Kyle Robertson treating adults Provident research and news Kyle Robertson

Cerebral Stops New Prescriptions for ADHD Meds Effective May 9

Reading now: 596

May 4, 2022Cerebral Inc. will stop writing new prescriptions for controlled substances that treat attention deficit hyperactivity disorder (ADHD), such as Adderall and Ritalin, effective May 9, in states where prescribing services exist.

Current patients will continue to receive medications prescribed by the digital mental healthcare provider prior to that deadline.

The company is calling this a “pause” of its ADHD services, and not a permanent cessation of prescribing services for stimulant medications.“Clinical quality and safety are at the forefront of what we do, which is why we have decided to pause part of our ADHD service line,” wrote Kyle Robertson, CEO and founder of Cerebral, in a recent staff memo. “Based on recent feedback from stakeholders, it is clear that this has become a distraction from our focus to democratize access to mental healthcare services, provide treatment for more patients, and add service lines for new conditions.”The company has faced recent backlash for its prescribing practices and marketing strategies.

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles